Pfizer Inc: Form 10-Q for the period ended Apr 3, 2022
Filed with the SEC on May 11, 2022 and accepted by EDGAR at May 11, 2022, 16:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-04-03. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-01-01 to 2022-04-03 | $25.66bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-01-01 to 2022-04-03 | $9.98bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2022-01-01 to 2022-04-03 | $2.59bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2022-01-01 to 2022-04-03 | $322.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-01-01 to 2022-04-03 | $1.17bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-01-01 to 2022-04-03 | $7.86bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-01-01 to 2022-04-03 | $1.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-01-01 to 2022-04-03 | $1.40 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-01-01 to 2022-04-03 | 5,758,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-01-01 to 2022-04-03 | $6.54bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-01-01 to 2022-04-03 | $643.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2022-01-01 to 2022-04-03 | $2.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-04-03 | $2.47bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-04-03 | $54.42bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-04-03 | $183.84bn | us-gaap:Assets |
| Current liabilities | At period end2022-04-03 | $39.27bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-04-03 | $101.16bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-04-03 | $35.66bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-04-03 | $260.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-04-03 | $82.42bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000078003-22-000071. Last ingested by Listed: Nov 12, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.